Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad-500037, India.
Org Biomol Chem. 2021 Jan 28;19(4):738-764. doi: 10.1039/d0ob02181d. Epub 2021 Jan 18.
Nitrogen-containing heterocyclic scaffolds constitute nearly 75% of small molecules which favorably act as drug candidates. For the past few decades, numerous natural and synthetic indole-based scaffolds have been reported for their diverse pharmacological profiles. In particular, indole-fused azepines, termed azepinoindolones, have come under the radar of medicinal chemists owing to their synthetic and pharmacological importance. A plethora of literature reports has been generated thereof, which calls for the need for the compilation of information to understand their current status in drug discovery. Accumulating reports of evidence suggest that compounds containing this privileged scaffold display their cytotoxic effects via inhibition of kinase, topoisomerase I, mitochondrial malate dehydrogenase (mMDH), and tubulin polymerization and as DNA minor groove binding agents. Herein, we endeavor to present a closer look at the advancements of various synthetic and derivatization methods of azepinoindolone-based compounds. We have further extended our efforts to discuss the pharmacological effects of azepinoindolones in the whole range of medicinal chemistry as anti-Alzheimer, anticancer, anti-inflammatory, antidiabetic, antileishmanial, and antipyranosomal agents and as drug delivery vectors. Our analysis of recent advances reveals that azepinoindolones will continue to serve as potential pharmaceutical modalities in the years to come and their substantial pool of synthetic methods will be ever expanding.
含氮杂环骨架几乎占了 75%的小分子药物候选物。在过去的几十年中,许多天然和合成的吲哚基骨架因其多样化的药理学特性而被报道。特别是吲哚并氮杂环庚烷,称为氮杂吲哚酮,由于其合成和药理学的重要性,引起了药物化学家的关注。大量的文献报道已经产生,这就需要对信息进行编译,以了解它们在药物发现中的现状。越来越多的证据表明,含有这种特权骨架的化合物通过抑制激酶、拓扑异构酶 I、线粒体苹果酸脱氢酶 (mMDH)、微管聚合以及作为 DNA 小沟结合剂来显示其细胞毒性作用。在此,我们努力更仔细地研究基于氮杂吲哚酮的化合物的各种合成和衍生化方法的进展。我们还进一步努力讨论了氮杂吲哚酮在整个药物化学领域的药理作用,作为抗阿尔茨海默病、抗癌、抗炎、抗糖尿病、抗利什曼病和抗吡喃糖药物以及药物输送载体。对最新进展的分析表明,氮杂吲哚酮在未来几年将继续作为潜在的药物模式,其大量的合成方法将不断扩展。